Drug Profile
Research programme: galectin inhibitors - Cancure
Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Cancure
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Angiogenesis inhibitors; Galectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for research development in Cancer in Australia
- 11 Sep 2020 Early research is ongoing for Cancer in Australia (Cancure pipeline, September 2020)
- 11 Sep 2020 Cancure has patent protection for its galectin inhibitors in USA and Australia (Cancure website, September 2020)